We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands ...
Summit Therapeutics' ivonescimab outperforms Keytruda in Phase 3 lung cancer trials. Crucial Western market approval depends ...
FDA sets PDUFA goal date of May 24, 2025MORRISVILLE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for ...
PTC Therapeutics, Inc. announced today that the European Commission (EC) has adopted the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to ...
21h
Zacks Investment Research on MSNBEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA ClearanceBeam Therapeutics Inc. BEAM announced that the FDA has cleared the investigational new drug (IND) application to begin ...
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ...
19h
Zacks Investment Research on MSNUnited Therapeutics (UTHR) Down 4.8% Since Last Earnings Report: Can It Rebound?A month has gone by since the last earnings report for United Therapeutics (UTHR). Shares have lost about 4.8% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...
Onvida Health is bringing a new era of precision and early detection to lung cancer care in Yuma. The hospital has introduced ...
Focused on the evaluation of strategic alternativesAdopted a restructuring plan to extend capital resources, incurring a reduction in workforce ...
NUZ-001 slowed respiratory declines in ALS patients in a Phase 1 trial, and Neurizon is working to ready it for the HEALEY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results